Cidara Therapeutics Inc. announced plans to present new data highlighting Cloudbreak, the company’s immunotherapy discovery platform and antiviral program, at the World Antimicrobial Resistance Congress.
The platform is initially being used to develop candidates to prevent and treat multidrug-resistant gram-negative bacterial and viral infections.
According to Cidara, Cloudbreak antibody-drug conjugates are different from traditional antibiotics and antivirals because they have the ability to physically link pathogens to immune components to kill or prevent fungal, bacterial or viral pathogens via dual killing mechanisms.
The fourth annual World Antimicrobial Resistance Congress, being held in Washington, D.C., on Oct. 25 and 26, addresses all aspects of antimicrobial resistance, including research and development, diagnostics and stewardship initiatives.
Cidara’s presentation, “Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as countermeasures against multi-drug resistant bacterial infections," is scheduled for Friday, Oct. 26.
“We believe that our Cloudbreak antiviral program represents a fundamentally new approach to prevent and treat influenza,” Cidara President and CEO Jeffrey Stein, PhD, told Infectious Disease News. “It combines the broad-spectrum potency of small molecule drugs, such as Tamiflu, with the long acting protection of vaccines.”
Disclosure: Stein is CEO of Cidara Therapeutics.